ABBOTT REPORTS FIRST-QUARTER RESULTS

Our key products helped deliver impressive growth, exceeding expectations and jump-starting another strong year.

Abbott Reports First-Quarter Results

Apr 17 2019

We just closed the books on the first quarter of 2019 and our key products are helping to deliver another strong start for Abbott.

For the quarter, we delivered sales growth of more than 7% (on an organic basis) and exceeded our previous ongoing earnings-per-share guidance thanks to key products such as FreeStyle Libre, Alinity and MitraClip. We are also seeing several other bright spots throughout our portfolio in our medical devices, nutrition and established pharma businesses.

And, our innovative pipeline and focused execution is continuing to pay off. We saw more than 10 significant product approvals and developments in the first quarter alone.

Some of the highlights include:

  • MitraClip™ received a new, expanded indication in the U.S. to treat advanced heart failure patients with significant secondary mitral regurgitation, or a leaky heart valve.
  • Alinity, our highly-differentiated new suite of diagnostics systems, was selected by one of the largest reference labs in the U.S. to conduct testing for millions of patients. And Alinity™ m, the latest molecular testing platform for infectious disease, was approved in Europe.*
  • The FreeStyle Libre System, our revolutionary glucose-monitoring system, continues to see unprecedented uptake as we work to take connected care to the next level. We've partnered with Novo Nordisk to enable insulin data sharing between connected insulin pens and FreeStyle® LibreLink and LibreView.

For full financials, you can read our press release, or take a look at some additional materials below:

Abbott's Chairman and CEO Miles D. White shared his views on first-quarter performance:

 

 

Learn more about Abbott's first-quarter 2019 results:

 

 

Download a summary of Abbott's earnings highlights here.

2019 First-Quarter Results Infographic

For more information on Abbott's earnings results, see the news release.

*Alinity m is in development and not commercially available in the United States for diagnostic use.

 

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?